Meeting Banner
Abstract #0084

Preclinical MRI Reveals Bevacizumab Mitigates Radiation Necrosis

X. Jiang1, John A. Engelbach2, Jeremy Cates3, Dinesh K. Thotala4, RE Drzymala4, D.E. Hallahan4, JJH J.H. Ackerman5, Joel R. Garbow6

1Chemistry, Washington Univ. in st. louis, st louis, MO, United States; 2Radiology, Washington Univ. in st. louis, st louis, MO, United States; 3Radiation Oncology, Washington University in Saint Louis, st louis, MO, United States; 4Radiation Oncology, Washington Univ. in st. louis, st louis, MO, United States; 5Chemistry, Washington University in St. Louis, st louis, MO, United States; 6Radiology, Washington University in Saint Louis, st louis, MO, United States

Bevacizumab, is a powerful anti-angiogenic used in the treatment of tumors. Radiation necrosis, a severe but late occurring injury to normal tissue within and surrounding a radiation treatment field, has been suggested resulting from increases in vascular permeability (leakiness). Bevacizumab may help to repair leaky capillaries and thereby mitigate radiation necrosis. We have recently developed a novel mouse model of radiation necrosis using Gamma Knife irradiation. Here, we use small-animal MRI to monitor the therapeutic effect of bevacizumab and of mouse bevacizumab (B20-4.1.1), which is capable of high-affinity binding to both human and murine VEGF-A.

Abstract PDF Presentation Video

Keywords

accurately action affinity analyze animal anti antibodies antibody antigen approved audience barrier binding blocking blood blue brain cancer capillaries chemistry clearly clinicians cohort cohorts comparative contrast control curves demonstrating derived described developed directed disappeared distribution division dose efficacy efforts endothelial enhanced evident features female field fits function gamma greater green hemisphere hemispheric histogram human humanized identifying inhibits injury intensities intensity international investigative irradiated irradiation laboratory late lead least likely malignant medicine mice mitigates mitigative model monitored monoclonal mouse necrosis necrotic normalized novel occurring occurs oncology ongoing ophthalmology panel patients period periods phys physics plotted post powerful process progress progression quantified quantitatively radiation radiology rapidly reaching recapitulates received recently repair representative response reveals scanner science severe slices slope slow squares strategy studies subjects surrounding symmetric taken target therapeutic therapy thereby threshold tissue treated treatment tumor tumors twice typically unit univ untreated variety vascular visual volume volumes volumetric week weekly weeks whereby wide